Yuyin Jiang
Coordinator 4, Research SupportCards
About
Research
Publications
2026
HOX code–based stratification reveals RUNX1T1–HDAC reprogramming as a targetable driver of lineage plasticity across cancers
Jiang Y, Cheng S, Zhang CY, Jin X, Li L, Shin HE, Alrefai A, Luo A, Xu Y, Kim IY, Mu P. HOX code–based stratification reveals RUNX1T1–HDAC reprogramming as a targetable driver of lineage plasticity across cancers. Cancer Letters 2026, 648: 218465. DOI: 10.1016/j.canlet.2026.218465.Peer-Reviewed Original ResearchThis study investigates how HOX gene expression patterns identify therapy-resistant cancer subtypes and demonstrates RUNX1T1-HDAC3 inhibition as a potential treatment strategy for aggressive cancers.
2024
ZNF397 Deficiency Triggers TET2-driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer
Xu Y, Yang Y, Wang Z, Sjostrom M, Jiang Y, Tang Y, Cheng S, Deng S, Wang C, Gonzalez J, Johnson N, Li X, Li X, Metang L, Mukherji A, Xu Q, Tirado C, Wainwright G, Yu X, Barnes S, Hofstad M, Chen Y, Zhu H, Hanker A, Raj G, Zhu G, He H, Wang Z, Arteaga C, Liang H, Feng F, Wang Y, Wang T, Mu P. ZNF397 Deficiency Triggers TET2-driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer. Cancer Discovery 2024, 14: 1496-1521. PMID: 38591846, PMCID: PMC11285331, DOI: 10.1158/2159-8290.cd-23-0539.Peer-Reviewed Original ResearchConceptsLineage plasticityTherapy resistanceProstate cancerCancer cellsAndrogen receptorResistance to AR-targeted therapiesLuminal lineageAR-targeted therapiesOvercome therapy resistanceTransition of cancer cellsEpigenetic regulatory machineryBona fide coactivatorTherapy responseAR signalingEpigenetic rewiringDrug resistanceTherapeutic strategiesEpigenetic reprogrammingProstateTherapyCancerPhenotypic plasticityRegulatory machineryAndrogenTranscriptional programs
Get In Touch
Contacts
Email
Mailing Address
Mu Lab
300 George st, Suite 6300
New Haven, Connecticut 06511
United States